Alogenic therapeutics inc (allo) Q1 2025 earnings call highlights: strategic progress in the middle …

Q: Can you explain the logistical problems that affect the enrollment of the Alpha3 study and how they are solved? Will the consent to screening also register in the study? A: David Chang, CEO, said that the delay in the registration was due to local problems, in particular to a lack of staff to cover the study, which led to a delay of three to four months from activating the location to patient screening. This was addressed and the patient's approval of the screening is now in agreement with the first assumptions. Geoffrey Parker, CFO, added that the increase in patient -screening activity validates their observations, although not all approved patients will register because they have to test the randomization of MRDs.

Q: Are there any differences in location-related factors between community and academic locations for Alpha3 and what is the likelihood of a preliminary EFS display by the end of next year? A: Zachary Roberts, CMO, noticed no significant difference between community and academic locations in terms of start -up times and screening activities. David Chang stated that they are deliberately silent about the time of the preliminary EFS display, but plan to provide further instructions after the lymphodepletion and the senselessness analysis in the first half of 2026.

Q: All locations have enough staff for Alpha3 and how high is the conversion rate from the consent to randomization? A: Zachary Roberts explained that the websites are generally well occupied, although the first facility took time. The conversion rate of the consent to randomization is not disclosed, but the process of consent to randomization includes variability due to the time of MRD tests and logistics.

Q: How does the expansion to international locations affect the Alpha3 study and are there regulatory effects? A: Zachary Roberts explained that international expansion should not introduce heterogeneity in the patient mix, since R-Chop is the global standard for DLBCL treatment on the front. No regulatory implications are expected, and expansion is expected that the robustness of the study will be improved.

Q: In view of the careful approach, would you consider working together to work together the Allo-329 program? A: David Chang expressed the openness to the partnership of the autoimmune program, especially since it is not its core competence. The schedule for the detection of concept data was expanded to the first half of 2026 to contain clinical updates that reflect the feedback from investigators and a careful approach.

For the complete protocol of the earnings call, see the full profit call transcription.

This article first appeared on Gurufocus.